NewAmsterdam Leadership Tuesday, September 29, 2026 0.00 Neutral

NAMS Doses First SPINOZA Participant

NewAmsterdam Pharma began a Phase 2b trial of obicetrapib for preclinical Alzheimer's, shifting focus beyond cardiovascular indications.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed